Efficacy of Daratumumab-Based Regimens for Extramedullary Pulmonary Plasmacytoma: A Case Report

Cancer Rep (Hoboken). 2024 Nov;7(11):e2149. doi: 10.1002/cnr2.2149.

Abstract

Introduction: Multiple myeloma (MM) with pulmonary extramedullary disease is rare and usually associated with poor prognosis, and no data on daratumumab-based regimens have been reported yet.

Case presentation: Here, a 64-year-old man with pulmonary plasmacytoma received daratumumab-based regimens and has achieved a very good partial response with lung mass disappearance and overall survival of 16 months. He did not receive autologous stem cell transplantation because of several comorbidities, such as severe drug-induced neuropathy and JAK2-mutated myeloproliferative neoplasm with marked splenomegaly.

Conclusions: We showed the efficacy of daratumumab in combination with targeted therapies for the treatment of pulmonary MM.

Keywords: daratumumab; extramedullary disease; multiple myeloma.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal* / administration & dosage
  • Antibodies, Monoclonal* / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Lung Neoplasms* / pathology
  • Male
  • Middle Aged
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / pathology
  • Plasmacytoma* / diagnosis
  • Plasmacytoma* / drug therapy
  • Plasmacytoma* / pathology
  • Plasmacytoma* / therapy
  • Treatment Outcome

Substances

  • daratumumab
  • Antibodies, Monoclonal